# Biofourmis

> Biofourmis is a global digital health and technology-enabled care delivery company founded in 2015, specializing in AI-driven virtual care, remote patient monitoring (RPM), and digital therapeutics.

---
Type: post
Date: 2025-01-02
Reading time: 15 min read
Tags: competitor-analysis, enterprise
---

# Biofourmis - Comprehensive Research Report

*Research Completed: 2025-01-02*
*Research Depth: Comprehensive*

---

## Executive Summary

Biofourmis is a global digital health and technology-enabled care delivery company founded in 2015, specializing in AI-driven virtual care, remote patient monitoring (RPM), and digital therapeutics. Originally headquartered in Singapore and later moving operations to Boston, Massachusetts, the company reached unicorn status in 2022 with a $1.3 billion valuation after raising $300 million in Series D funding. The company has undergone significant transformation in 2023-2024, including founder CEO departure, strategic layoffs, and a major merger with CopilotIQ in October 2024, followed by selling its life sciences business to ActiGraph in January 2025.

**Key Facts at a Glance:**
| Attribute | Value |
|-----------|-------|
| **Founded** | 2015 |
| **Headquarters** | Boston, Massachusetts (US); Singapore operations |
| **Stage** | Growth Stage (Post-Merger) |
| **Total Funding** | ~$463-465M |
| **Last Round** | Series D - $320M (April-August 2022) |
| **Employees** | ~150 (estimated post-restructuring) |
| **Valuation** | $1.3B (April 2022) |
| **Status** | Merged with CopilotIQ (October 2024); Life Science business sold to ActiGraph (January 2025) |

---

## 1. Company Overview

### Basic Information

**Legal Name**: Biofourmis Singapore Pte. Ltd. / Biofourmis, Inc. [Accessed 2025-01-02](https://www.biofourmis.com)
**Website**: https://www.biofourmis.com
**Founded**: 2015 [Accessed 2025-01-02](https://www.biofourmis.com)
**Headquarters**: 117 Kendrick St, Suite 300, Needham, Massachusetts 02494, US [Accessed 2025-01-02](https://www.apollo.io)
**Company Type**: Private (merged entity with CopilotIQ)
**Company Stage**: Growth Stage / Post-Merger

### Mission & Vision

**Mission**: "To bring high-quality care and life-changing clinical trials to any person, anywhere" and "redefine the future of healthcare delivery by extending care to the comfort of patients' homes" [2024-10-21](https://www.biofourmis.com/news-insights/copilotiq-and-biofourmis-merge-to-create-the-first-end-to-end-platform-for-ai-driven-in-home-care)

**Vision**: Transform healthcare from reactive treatment to proactive prevention, and from generalized to deeply personalized, data-driven care [2024-10-21](https://www.biofourmis.com/news-insights/copilotiq-and-biofourmis-merge-to-create-the-first-end-to-end-platform-for-ai-driven-in-home-care)

### Company Description

Biofourmis is a global digital health and biotechnology company that utilizes predictive analytics and FDA-cleared AI algorithms to analyze over 120 biomarkers in real-time. The company's technology enables proactive interventions, improved patient outcomes, and reduced hospital readmissions. The platform combines passive inputs via continuous monitoring devices, active inputs from episodic monitoring devices, and patient feedback to provide a complete picture of patient health status.

The company operates across multiple healthcare segments: care delivery solutions for hospitals and health systems (Care@Home), virtual care services, digital therapeutics, and clinical trial support for life sciences companies. Biofourmis claims to have served over 1 million patients through its connected platform [Accessed 2025-01-02](https://www.apollo.io).

Following the October 2024 merger with CopilotIQ, the combined entity positions itself as the industry's first AI-driven platform delivering in-home care across the full spectrum from pre-surgical optimization to acute, post-acute, and chronic care [2024-10-21](https://www.biofourmis.com/news-insights/copilotiq-and-biofourmis-merge-to-create-the-first-end-to-end-platform-for-ai-driven-in-home-care).

---

## 2. Financial Profile

### Funding Summary

**Total Funding Raised**: ~$463-465M [High confidence: [2022-04-26](https://www.biofourmis.com/news-insights/biofourmis-receives-significant-growth-investment-from-general-atlantic-to-surpass-unicorn-status), [Accessed 2025-01-02](https://www.texau.com/profiles/biofourmis)]
**Number of Rounds**: 5+ (Angel, Series A, Series B, Series C, Series D with extension)
**Most Recent Round**: Series D Extension - $20M (August 2022)
**Most Recent Valuation**: ~$1.3B (April 2022) [High confidence: [2022-04-26](https://www.prnewswire.com/news-releases/biofourmis-receives-significant-growth-investment-from-general-atlantic-to-propel-company-to-unicorn-status-301532617.html)]

### Complete Funding History

| Round | Amount | Date | Lead Investor | Other Investors | Valuation | Source |
|-------|--------|------|---------------|-----------------|-----------|--------|
| Series D Extension | $20M | Aug 2022 | Intel Capital | - | - | [2022-08-10](https://www.intelcapital.com/biofourmis-raises-additional-funding-from-intel-capital-in-series-d-extension-and-names-top-healthcare-leaders-to-its-board/) |
| Series D | $300M | Apr 2022 | General Atlantic | CVS Health, Openspace Ventures, EDBI | ~$1.3B | [2022-04-26](https://www.biofourmis.com/news-insights/biofourmis-receives-significant-growth-investment-from-general-atlantic-to-surpass-unicorn-status) |
| Series C | $100M | Sep 2020 | SoftBank Vision Fund 2 | Openspace Ventures, MassMutual Ventures, Sequoia Capital, EDBI | - | [2020-09-03](https://www.prnewswire.com/news-releases/biofourmis-closes-100-million-series-c-funding-round-led-by-softbank-vision-fund-2-to-accelerate-us-and-global-expansion-301123515.html) |
| Series B | $35M | May 2019 | Sequoia Capital | MassMutual Ventures, EDBI, Jianke, Openspace Ventures, SGInnovate | - | [2019-05-21](https://www.prnewswire.com/news-releases/biofourmis-closes-35-million-series-b-financing-round-to-advance-artificial-intelligence-powered-digital-therapeutics-platform-300853681.html) |
| Series A | $5-10.3M | Dec 2017 | NSI Ventures | STMicroelectronics, Swiss RE | - | [Accessed 2025-01-02](https://www.apollo.io) |
| Angel | $1M | Aug 2016 | SpesNet, Eden Strategy | - | - | [Accessed 2025-01-02](https://www.apollo.io) |

### Detailed Round Information

**Series D & Extension**: $320M total (April-August 2022)
- Lead Investor: General Atlantic [2022-04-26](https://www.biofourmis.com/news-insights/biofourmis-receives-significant-growth-investment-from-general-atlantic-to-surpass-unicorn-status)
- Participating Investors: CVS Health, Intel Capital, Openspace Ventures, EDBI, existing investors
- Valuation: ~$1.3 billion (unicorn status achieved)
- Use of Funds: Scale virtual care offerings, Care@Home platform expansion, digital medicine initiatives, clinical trials for digital therapies
- Board Addition: Dr. Omar Ishrak appointed Chairman

**Series C**: $100M (September 2020)
- Lead Investor: SoftBank Vision Fund 2 [2020-09-03](https://techcrunch.com/2020/09/02/softbank-vision-fund-2-leads-100-million-series-c-in-digital-therapeutics-company-biofourmis/)
- Participating Investors: Openspace Ventures, MassMutual Ventures, Sequoia Capital, EDBI
- Use of Funds: US and global expansion

**Series B**: $35M (May 2019)
- Lead Investor: Sequoia Capital
- Use of Funds: Advance AI-powered digital therapeutics platform

### Complete Investor List

- **General Atlantic**: Series D (Lead)
- **SoftBank Vision Fund 2**: Series C (Lead)
- **Sequoia Capital**: Series B (Lead), Series C
- **CVS Health**: Series D
- **Intel Capital**: Series D Extension
- **MassMutual Ventures**: Series B, Series C
- **Openspace Ventures**: Series B, Series C, Series D
- **EDBI (Singapore)**: Series A, Series B, Series C, Series D
- **NSI Ventures**: Series A
- **STMicroelectronics**: Series A
- **Swiss RE**: Series A
- **SGInnovate**: Series B
- **Jianke**: Series B
- **SpesNet**: Angel
- **Eden Strategy**: Angel
- **Bessemer Venture Partners**: Post-merger investor (2024)

### Revenue & Financial Metrics

**Annual Revenue**: ~$210M [Low confidence: Apollo estimate [Accessed 2025-01-02](https://www.apollo.io) - unverified]
**Revenue Model**: Enterprise SaaS/platform licensing to health systems, pharma partnerships, care delivery services
**Profitability**: Not profitable as of 2023; investor pressure to focus on profitability over growth [2023-09-06](https://pharmaphorum.com/news/biofourmis-quietly-parts-company-ceo-rajput)

---

## 3. Product & Technology

### Product Overview

Biofourmis operates a comprehensive digital health platform centered on the Biovitals Analytics Engine, offering solutions across care delivery for health systems and clinical trial support for life sciences companies.

### Product Portfolio

| Product | Description | Target Segment | FDA Status |
|---------|-------------|----------------|------------|
| **Biovitals Analytics Engine** | AI-powered analytics platform analyzing 120+ biomarkers | Enterprise | FDA 510(k) cleared (2019) |
| **BiovitalsHF** | Digital therapeutic for heart failure management | Health Systems, Cardiologists | FDA Breakthrough Device Designation (2021) |
| **Care@Home Platform** | Virtual care platform for hospital-at-home programs | Health Systems, Payors | FDA-cleared components |
| **Biofourmis Care** | Virtual specialty care services for chronic conditions | Enterprise Healthcare | - |
| **Biofourmis Connect** | Digital clinical trial platform for life sciences | Pharma/Biotech (Sold to ActiGraph Jan 2025) | - |
| **Everion Biosensor** | Clinical-grade wearable biosensor (via Biovotion acquisition) | Enterprise | CE marked |

### Core Capabilities

- AI/ML-powered predictive analytics for early clinical deterioration detection [2022-04-26](https://www.biofourmis.com/news-insights/biofourmis-receives-significant-growth-investment-from-general-atlantic-to-surpass-unicorn-status)
- Continuous remote patient monitoring across 120+ biomarkers [Accessed 2025-01-02](https://www.apollo.io)
- Personalized patient baselines (comparing patient to their own normal state vs. population norms)
- 24/7 virtual clinical care team with licensed health professionals
- Device-agnostic sensor integration platform
- Real-time alerts with reduced false positives
- EMR/EHR integration capabilities
- Dynamic care pathways for therapeutic interventions

### Technology Approach

**Architecture**: Cloud-based SaaS platform with edge computing capabilities [2022-08-10](https://www.intelcapital.com/biofourmis-raises-additional-funding-from-intel-capital-in-series-d-extension-and-names-top-healthcare-leaders-to-its-board/)
**Tech Stack**: AI/ML algorithms, cloud infrastructure (AWS Route 53), Salesforce CRM, HubSpot, Zendesk [Accessed 2025-01-02](https://www.apollo.io)
**Key Technical Differentiators**:
- FDA-cleared AI algorithms for physiological monitoring [2019-10-03](https://www.prnewswire.com/news-releases/biofourmis-biovitals-analytics-engine-receives-fda-clearance-for-ambulatory-physiologic-monitoring-300930306.html)
- Device-agnostic approach (works with multiple wearables/sensors)
- Personalized rather than population-based baselines
- Integration of passive monitoring + active inputs + patient feedback

### FDA Regulatory Milestones

- **October 2019**: Biovitals Analytics Engine receives FDA 510(k) clearance for ambulatory physiologic monitoring [2019-10-03](https://www.prnewswire.com/news-releases/biofourmis-biovitals-analytics-engine-receives-fda-clearance-for-ambulatory-physiologic-monitoring-300930306.html)
- **July 2021**: BiovitalsHF receives FDA Breakthrough Device Designation - first-ever for a digital therapeutic for heart failure [2021-07-29](https://www.bioworld.com/articles/509908-fda-grants-breakthrough-status-to-biofourmis-digital-therapy-for-heart-failure)

### Intellectual Property

**Patents**: 60+ global patents covering wearable and sensor technology (acquired via Biovotion) [2019-11-18](https://www.biofourmis.com/news-insights/biofourmis-acquires-of-biovotion-ag-completing-biovitals-platform)

### Acquisitions

| Company | Date | Purpose | Source |
|---------|------|---------|--------|
| **Biovotion AG** | Nov 2019 | Clinical-grade wearable biosensor (Everion) + 60+ patents | [2019-11-18](https://www.biofourmis.com/news-insights/biofourmis-acquires-of-biovotion-ag-completing-biovitals-platform) |
| **Gaido Health** | Apr 2020 | Oncology digital therapeutics (from Takeda) | [2020-04-16](https://www.prnewswire.com/news-releases/digital-therapeutics-leader-biofourmis-expands-into-oncology-market-with-strategic-acquisition-of-gaido-health-301041721.html) |
| **PhysioWave** | - | Remote patient monitoring | [Accessed 2025-01-02](https://www.apollo.io) |

---

## 4. Leadership & Team

### Executive Team (Post-Merger 2024)

| Role | Name | Background | Since | Source |
|------|------|------------|-------|--------|
| **CEO** | David Koretz | CEO of CopilotIQ; leads combined entity | Oct 2024 | [2024-10-21](https://www.biofourmis.com/news-insights/copilotiq-and-biofourmis-merge-to-create-the-first-end-to-end-platform-for-ai-driven-in-home-care) |
| **Former Interim CEO** | Ben Wanamaker | Partner at General Atlantic | Aug 2023 - Oct 2024 | [2023-09-06](https://pharmaphorum.com/news/biofourmis-quietly-parts-company-ceo-rajput) |

### Board of Directors

| Name | Role | Affiliation | Source |
|------|------|-------------|--------|
| **Dr. Omar Ishrak** | Chairman | Former CEO Medtronic; Former Chairman Intel | [2022-04-26](https://www.biofourmis.com/news-insights/biofourmis-receives-significant-growth-investment-from-general-atlantic-to-surpass-unicorn-status) |
| **Ben Wanamaker** | Board Member | Partner, General Atlantic | [2023-09-06](https://pharmaphorum.com/news/biofourmis-quietly-parts-company-ceo-rajput) |
| **Kuldeep Singh Rajput** | Board Member | Founder (retained seat after CEO departure) | [2023-09-06](https://pharmaphorum.com/news/biofourmis-quietly-parts-company-ceo-rajput) |

### Founders

| Name | Role | Background | Status | Source |
|------|------|------------|--------|--------|
| **Kuldeep Singh Rajput** | Co-Founder, Former CEO | Forbes 30 Under 30; now CEO at OutcomesAI | Departed Aug 2023; Board seat retained | [2023-09-06](https://pharmaphorum.com/news/biofourmis-quietly-parts-company-ceo-rajput), [Accessed 2025-01-02](https://www.linkedin.com/in/rajputkuldeepsingh) |
| **Wendou Niu** | Co-Founder, MD | - | - | [Accessed 2025-01-02](https://equityzen.com/company/biofourmispteltd/) |

### Team Size & Growth

**Current Employees**: ~150 [Medium confidence: Apollo estimate [Accessed 2025-01-02](https://www.apollo.io)]
**2023 Layoffs**: 120 employees globally (48 in US) - primarily operational and administrative roles [2023-07-26](https://www.mddionline.com/business/biofourmis-cuts-120-jobs-worldwide-including-48-in-us)
**Locations**: Boston (HQ), Singapore, India [Accessed 2025-01-02](https://www.apollo.io)

### Leadership Changes Timeline

- **January 2020**: Hired COO and CTO from pharma/tech backgrounds [2020-01-27](https://www.biofourmis.com/news-insights/biofourmis-names-pharma-and-tech-veterans-as-coo-and-cto)
- **April 2022**: Dr. Omar Ishrak appointed Board Chairman [2022-04-26](https://www.biofourmis.com/news-insights/biofourmis-receives-significant-growth-investment-from-general-atlantic-to-surpass-unicorn-status)
- **August 2023**: Founder/CEO Kuldeep Singh Rajput steps down; Ben Wanamaker (General Atlantic) appointed interim CEO [2023-09-06](https://pharmaphorum.com/news/biofourmis-quietly-parts-company-ceo-rajput)
- **October 2024**: David Koretz becomes CEO of merged CopilotIQ/Biofourmis entity [2024-10-21](https://www.biofourmis.com/news-insights/copilotiq-and-biofourmis-merge-to-create-the-first-end-to-end-platform-for-ai-driven-in-home-care)

---

## 5. Customers & Market

### Target Market

**Primary Segment**: Enterprise Healthcare (Health Systems, Hospitals, Payors) [Accessed 2025-01-02](https://www.biofourmis.com)
**Secondary Segment**: Life Sciences/Biopharma (clinical trials) - business sold to ActiGraph January 2025
**Industry Verticals**: Hospital-at-home, post-acute care, chronic disease management, cardiovascular, oncology, pulmonology
**Geographic Focus**: United States (primary), global expansion
**Ideal Customer Profile**: Large health systems seeking hospital-at-home capabilities, payors focused on value-based care, pharma companies conducting digital clinical trials

### Customer Base

**Total Patients Served**: 1+ million (company claim) [Accessed 2025-01-02](https://www.apollo.io)
**Health System Partnerships**: 10+ globally as of Series C [2020-09-03](https://www.prnewswire.com/news-releases/biofourmis-closes-100-million-series-c-funding-round-led-by-softbank-vision-fund-2-to-accelerate-us-and-global-expansion-301123515.html)
**Pharma Partnerships**: 7+ pharmaceutical companies as of Series C [2020-09-03](https://www.prnewswire.com/news-releases/biofourmis-closes-100-million-series-c-funding-round-led-by-softbank-vision-fund-2-to-accelerate-us-and-global-expansion-301123515.html)

### Named Customers

| Customer | Industry | Relationship | Source |
|----------|----------|--------------|--------|
| **Orlando Health** | Health System | Multi-year hospital-at-home program (1,000+ patients served) | [2023-01-23](https://www.biofourmis.com/news-insights/orlando-health-selects-biofourmis-to-enable-optimal-hospital-level-care-in-patients-homes) |
| **AdventHealth** | Health System | Hospital-at-home + post-acute RPM program (Central Florida) | [2025-01-06](https://biofourmis.com/news-insights/biofourmis-selected-by-adventhealth-to-support-whole-person-care-with-new-acute-care-at-home-program) |
| **GE HealthCare** | Technology Partner | Strategic collaboration for care-at-home solutions | [2024-02-26](https://www.prnewswire.com/news-releases/ge-healthcare-and-biofourmis-collaborate-to-extend-patient-monitoring-outside-the-hospital-with-virtual-care-at-home-solutions-302070324.html) |
| **Novartis** | Pharma | Heart failure patient management program (Asia, global expansion) | [2019-11-18](https://www.biofourmis.com/news-insights/biofourmis-to-offer-digital-medicine-heart-failure-patients) |
| **AstraZeneca** | Pharma | Partnership (mentioned in press) | [2023-09-06](https://pharmaphorum.com/news/biofourmis-quietly-parts-company-ceo-rajput) |
| **Chugai Pharma** | Pharma | Partnership (mentioned in press) | [2023-09-06](https://pharmaphorum.com/news/biofourmis-quietly-parts-company-ceo-rajput) |
| **Top-20 Pharma** | Pharma | Four new agreements (2024) for digital clinical trials | [2024-02-13](https://www.prnewswire.com/news-releases/biofourmis-secures-four-new-agreements-with-top-20-pharma-on-strength-of-platform-for-digital-clinical-trials-and-digital-biomarkers-302060316.html) |
| **CVS Health** | Payor/Retail | Strategic investor + customer | [2022-04-26](https://www.biofourmis.com/news-insights/biofourmis-receives-significant-growth-investment-from-general-atlantic-to-surpass-unicorn-status) |
| **Tenet Healthcare** | Health System | Investor | [2023-09-06](https://pharmaphorum.com/news/biofourmis-quietly-parts-company-ceo-rajput) |
| **SCAN Group** | Payor | Investor | [2023-09-06](https://pharmaphorum.com/news/biofourmis-quietly-parts-company-ceo-rajput) |

### Customer Outcomes (Company Claims)

- 70% reduction in 30-day hospital readmissions [2022-04-26](https://www.biofourmis.com/news-insights/biofourmis-receives-significant-growth-investment-from-general-atlantic-to-surpass-unicorn-status)
- 38% reduction in cost of care [2022-04-26](https://www.biofourmis.com/news-insights/biofourmis-receives-significant-growth-investment-from-general-atlantic-to-surpass-unicorn-status)
- Orlando Health: 1,000+ patients served in hospital-at-home program (launched Feb 2023) [Accessed 2025-01-02](https://www.linkedin.com/posts/biofourmis_orlando-health-expands-hospital-at-home-program-activity-7216425862294831104-WrNn)

---

## 6. Business Model & Go-to-Market

### Revenue Model

**Primary Revenue Streams**:
- Enterprise SaaS licensing for Care@Home platform
- Per-patient monitoring fees
- Clinical care services (virtual care teams)
- Life sciences platform licensing (sold to ActiGraph)
- Pharma partnerships for digital clinical trials

**Pricing Model**: Enterprise contracts, likely multi-year agreements [Medium confidence: inferred from customer announcements]

### Go-to-Market Strategy

**Sales Model**: Enterprise sales-led, strategic partnerships
**Key Partnerships**:
- GE HealthCare: Distribution partnership for US market [2024-02-26](https://www.prnewswire.com/news-releases/ge-healthcare-and-biofourmis-collaborate-to-extend-patient-monitoring-outside-the-hospital-with-virtual-care-at-home-solutions-302070324.html)
- Health system direct sales
- Pharma company partnerships

### Strategic Partnerships

| Partner | Type | Details | Source |
|---------|------|---------|--------|
| **GE HealthCare** | Distribution | GE distributes Biofourmis solutions to US customers | [2024-02-26](https://www.prnewswire.com/news-releases/ge-healthcare-and-biofourmis-collaborate-to-extend-patient-monitoring-outside-the-hospital-with-virtual-care-at-home-solutions-302070324.html) |
| **Novartis** | Pharma Alliance | BiovitalsHF deployment for heart failure patients | [2019-11-18](https://www.biofourmis.com/news-insights/biofourmis-to-offer-digital-medicine-heart-failure-patients) |
| **CopilotIQ** | Merger | Combined entity for full care continuum | [2024-10-21](https://www.biofourmis.com/news-insights/copilotiq-and-biofourmis-merge-to-create-the-first-end-to-end-platform-for-ai-driven-in-home-care) |

---

## 7. Competitive Context

### Company-Stated Differentiators

- First FDA Breakthrough Device Designation for a digital therapeutic for heart failure [2021-07-29](https://www.bioworld.com/articles/509908-fda-grants-breakthrough-status-to-biofourmis-digital-therapy-for-heart-failure)
- Personalized baselines vs. population-based monitoring [2022-04-26](https://www.biofourmis.com/news-insights/biofourmis-receives-significant-growth-investment-from-general-atlantic-to-surpass-unicorn-status)
- Device-agnostic platform supporting multiple wearables/sensors
- Combination of technology platform + 24/7 virtual clinical care team
- FDA-cleared AI algorithms analyzing 120+ biomarkers
- Full care continuum coverage (post-merger with CopilotIQ): pre-surgical to chronic care

### Market Context

**Industry**: Remote Patient Monitoring, Digital Therapeutics, Hospital-at-Home
**Market Drivers**:
- McKinsey estimates $265 billion worth of care services could shift to home by 2025 [2022-04-26](https://www.biofourmis.com/news-insights/biofourmis-receives-significant-growth-investment-from-general-atlantic-to-surpass-unicorn-status)
- Value-based care adoption
- Hospital capacity constraints
- Staff shortages
- COVID-19 acceleration of virtual care

**Competitive Landscape**:
- RPM providers (Current Health/Best Buy Health, Livongo/Teladoc, Health Recovery Solutions)
- Hospital-at-home platforms (Medically Home, Contessa/Amedisys)
- Digital therapeutics companies (Pear Therapeutics - bankrupt, Akili)

---

## 8. Recent Activity (Last 24 Months)

### Timeline

| Date | Event | Details | Source |
|------|-------|---------|--------|
| Jan 2025 | Acquisition | ActiGraph acquires Biofourmis Life Science business (Biofourmis Connect) | [2025-01-07](https://www.prnewswire.com/news-releases/actigraph-accelerates-clinical-trial-modernization-with-transformational-acquisition-of-biofourmis-life-science-business-302344216.html) |
| Jan 2025 | Partnership | AdventHealth selects Biofourmis for hospital-at-home program | [2025-01-06](https://biofourmis.com/news-insights/biofourmis-selected-by-adventhealth-to-support-whole-person-care-with-new-acute-care-at-home-program) |
| Oct 2024 | Merger | CopilotIQ and Biofourmis merge; David Koretz becomes CEO | [2024-10-21](https://www.biofourmis.com/news-insights/copilotiq-and-biofourmis-merge-to-create-the-first-end-to-end-platform-for-ai-driven-in-home-care) |
| Feb 2024 | Partnership | GE HealthCare collaboration for care-at-home solutions | [2024-02-26](https://www.prnewswire.com/news-releases/ge-healthcare-and-biofourmis-collaborate-to-extend-patient-monitoring-outside-the-hospital-with-virtual-care-at-home-solutions-302070324.html) |
| Feb 2024 | Customer Win | Four new Top-20 pharma agreements | [2024-02-13](https://www.prnewswire.com/news-releases/biofourmis-secures-four-new-agreements-with-top-20-pharma-on-strength-of-platform-for-digital-clinical-trials-and-digital-biomarkers-302060316.html) |
| Aug-Sep 2023 | Leadership | Founder/CEO Rajput departs; Ben Wanamaker (General Atlantic) interim CEO | [2023-09-06](https://pharmaphorum.com/news/biofourmis-quietly-parts-company-ceo-rajput) |
| Jul 2023 | Restructuring | 120 employees laid off globally (48 in US) | [2023-07-26](https://www.mddionline.com/business/biofourmis-cuts-120-jobs-worldwide-including-48-in-us) |
| Jan 2023 | Customer Win | Orlando Health multi-year agreement | [2023-01-23](https://www.biofourmis.com/news-insights/orlando-health-selects-biofourmis-to-enable-optimal-hospital-level-care-in-patients-homes) |

### Major Strategic Developments

**CopilotIQ Merger (October 2024)**:
The merger creates the first end-to-end AI-driven platform for in-home care, combining:
- CopilotIQ's chronic care management + patient engagement capabilities
- Biofourmis' acute/post-acute care + FDA-cleared algorithms
- New investment from General Atlantic, Openspace Ventures, Bessemer Venture Partners
- David Koretz (CopilotIQ CEO) leads combined entity

**ActiGraph Acquisition of Life Sciences Business (January 2025)**:
- Biofourmis Connect (life sciences/clinical trial platform) sold to ActiGraph
- Creates unified digital health solution for clinical research
- Biofourmis focuses on care delivery business post-transaction

---

## 9. Online Presence & Brand

### Social Media

| Platform | Handle/URL | Followers | Source |
|----------|------------|-----------|--------|
| LinkedIn | [/company/biofourmis](https://www.linkedin.com/company/biofourmis) | 43,397 | [Accessed 2025-01-02](https://www.linkedin.com/company/biofourmis) |
| Twitter/X | [@biofourmis](https://twitter.com/biofourmis) | - | [Accessed 2025-01-02](https://www.apollo.io) |
| Facebook | Biofourmis Singapore | - | [Accessed 2025-01-02](https://www.apollo.io) |

### Industry Recognition

- Forbes 30 Under 30 - Founder Kuldeep Singh Rajput
- CopilotIQ (merger partner) named to Fast Company's Most Innovative Companies 2024

---

## 10. Risk Factors & Concerns

### Documented Concerns

- **July 2023 Layoffs**: 120 employees globally (~25% of workforce at time), including 48 in US; primarily operational/administrative roles [2023-07-26](https://www.mddionline.com/business/biofourmis-cuts-120-jobs-worldwide-including-48-in-us)

- **CEO Departure (August 2023)**: Founder Kuldeep Singh Rajput stepped down abruptly; reports indicate investor pressure from General Atlantic to focus on profitability over growth [2023-09-06](https://pharmaphorum.com/news/biofourmis-quietly-parts-company-ceo-rajput)

- **Digital Health Industry Headwinds**: Sector-wide downturn in 2022-2023 affecting valuations and funding; notable bankruptcies of Pear Therapeutics and Babylon Health [2023-09-06](https://pharmaphorum.com/news/biofourmis-quietly-parts-company-ceo-rajput)

- **Business Unit Sale**: Life sciences business sold to ActiGraph (January 2025), indicating strategic refocus/potential need for capital [2025-01-07](https://www.prnewswire.com/news-releases/actigraph-accelerates-clinical-trial-modernization-with-transformational-acquisition-of-biofourmis-life-science-business-302344216.html)

- **Valuation Uncertainty**: $1.3B valuation from April 2022 may not reflect current value given layoffs, CEO departure, merger, and business unit sale

---

## 11. Research Methodology & Limitations

### Sources Used

**Primary Sources**:
- Biofourmis official press releases and news (biofourmis.com)
- SEC/regulatory filings (FDA 510(k) database)
- Company announcements via PRNewswire/BusinessWire

**Secondary Sources**:
- TechCrunch, STAT News, Fierce Healthcare, Pharmaphorum
- Apollo.io organization enrichment data
- LinkedIn company page
- Industry databases (Crunchbase references)

### Research Limitations

**Data Gaps**:
- Current employee count post-merger uncertain
- Revenue figures are estimates (Apollo data, unverified)
- Current valuation post-2023 restructuring unknown
- Detailed product pricing not publicly available
- Full customer list not disclosed

**Confidence Notes**:
- Funding history well-documented through press releases
- Post-merger organizational structure and leadership details limited
- Revenue/financial metrics are third-party estimates with low confidence

**Temporal Limitations**:
- Research current as of January 2, 2025
- Company undergoing significant transformation (merger completed Oct 2024, business sale Jan 2025)
- Some data from 2022-2023 may be outdated given restructuring

### Data Quality Summary

| Category | Completeness | Confidence |
|----------|--------------|------------|
| Basic Info | High | High |
| Funding | High | High |
| Product | High | High |
| Leadership | Medium | Medium |
| Customers | Medium | Medium |
| Financials | Low | Low |

---

## 12. Tags

`enterprise` `growth-stage` `saas` `ai-powered` `digital-therapeutics` `remote-patient-monitoring` `hospital-at-home` `healthcare`

**Tag Categories**:
- **Customer Segment**: `enterprise`
- **Product Approach**: `platform` `vertical-healthcare`
- **Stage**: `growth-stage`
- **Business Model**: `saas` `enterprise-sales`
- **Technology**: `ai-powered` `cloud-native`
- **Geographic**: `us-primary` `global`
- **Industry**: `healthcare` `digital-health` `remote-patient-monitoring` `digital-therapeutics`

---

*Research completed by Company Deep Researcher Agent*
*Date: 2025-01-02*